Literature DB >> 12113088

Wilms tumor: progress to date and future considerations.

P F Ehrlich1.   

Abstract

Wilms tumor is the most common tumor of renal origin found in children. In the last 50 years, remarkable progress has been made in the treatment and understanding of children with Wilms tumor. Through the development of multiagent chemotherapy and cooperative pediatric interdisciplinary groups conducting large randomized controlled clinical trials, survival has improved dramatically. In the next century it is expected that 80% of children with Wilms tumor will be long-term survivors. Therapy is progressing towards a risk-based management based not only on stage and histology but also incorporated genetic markers. This article reviews progress to date and possible future directions in the treatment of Wilms Tumor.

Entities:  

Mesh:

Year:  2001        PMID: 12113088     DOI: 10.1586/14737140.1.4.555

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

Review 1.  Wilms tumour: prognostic factors, staging, therapy and late effects.

Authors:  Sue C Kaste; Jeffrey S Dome; Paul S Babyn; Norbert M Graf; Paul Grundy; Jan Godzinski; Gill A Levitt; Helen Jenkinson
Journal:  Pediatr Radiol       Date:  2007-11-17

2.  Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children's Oncology Group/National Wilms Tumor Study Group.

Authors:  Peter F Ehrlich; Fernando A Ferrer; Michael L Ritchey; James R Anderson; Daniel M Green; Paul E Grundy; Jeffrey S Dome; John A Kalapurakal; Elizabeth J Perlman; Robert C Shamberger
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

3.  S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor.

Authors:  Mei-Hong Li; Teresa Sanchez; Ginger L Milne; Jason D Morrow; Timothy Hla; Fernando Ferrer
Journal:  J Urol       Date:  2009-01-20       Impact factor: 7.450

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.